Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour

Influenza Vaccine Clinical Trial

Official title:

Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04230343
• Other study ID #: 855 - 21/10/2016
• Status: Completed
• Phase: N/A
• Start date: November 13, 2016
• Est. completion date: March 25, 2017

Study information

• Verified date: January 2020
• Source: SB Istanbul Education and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 244
• Est. completion date: March 25, 2017
• Est. primary completion date: March 25, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients hospitalized at medical departments of the hospital who are on the day of discharge

Exclusion Criteria:

• Egg ellergy

• Previous allergic reaction to influenza vaccine

• Pregnancy

• Cognitive disability

Related Conditions & MeSH terms

• Behavioral Intervention
• Influenza Vaccine
• Influenza, Human
• Self-benefit
• Social-benefit

Intervention

Behavioral:
• Self-benefit message
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
• Other-benefit message
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.

Locations

Country	Name	City	State
Turkey	SB Istanbul Training and Research Hospital	Istanbul

Sponsors (2)

Lead Sponsor	Collaborator
SB Istanbul Education and Research Hospital	University of Nottingham

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccine uptake following the introduction of the pamphlet	Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.	On the same day, upto 24 hours
Secondary	Vaccine uptake in high and low risk group patients following the introduction of the pamphlet	Vaccine uptake in high and low risk group patients. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the social-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.	On the same day, upto 24 hours